drugset / Trial / NCT04501783
Study of Efficacy and Safety of TL-FVP-t vs. SOC in Patients With Mild to Moderate COVID-19
RandomizedParallel-groupOpen-labelTreatment
Summary
Randomized open-label multicenter parallel-group study of efficacy and safety of TL-FVP-t vs. standard of care therapy in patients with mild to moderate coronavirus disease (SARS-CoV-2/COVID-19)
Timeline
- Start
- 2020-05-20
- Primary completion
- 2020-07-29
- Completion
- 2020-08-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Favipiravir | Small molecule | 800 mg | Oral |
| Comparator | Chloroquine | Small molecule | — | — |
| Comparator | Hydroxychloroquine | Small molecule | — | — |
| Comparator | Recombinant Interferon Alpha | Protein / enzyme biologic | — | Intranasal |
| Comparator | Umifenovir | Small molecule | — | — |